American Journal of Obstetrics & Gynecology
Volume 188, Issue 1 , Pages 92-99 , January 2003

Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy

Received 14 February 2002 ,Revised 9 May 2002 ,Accepted 4 August 2002.

References 

  1. Rebar RW, Spitzer IB. The physiology and measurement of hot flushes. Am J Obstet Gynecol. 1987;156:1284–1288
  2. Speroff L, Symons J, Kempfert N, Rowan J, for the Femhrt Study Investigators . The effect of varying low dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms. Menopause. 2000;7:383–390
  3. Sullivan JM. Estrogen replacement therapy. Am J Med. 1996;101(suppl):50S–57S
  4. The Writing Group for the PEPI Trial . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199–209
  5. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 1996;348:429–432
  6. Marder K, Tang M-X, Alfaro B, Meija H, Cote L, Jacobs D, et al.  Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology. 1998;50:1141–1143
  7. Teede HJ. Controversies in HRT. Aust Fam Physician. 2002;31:413–418
  8. Resnick SM, Maki PM. Effects of hormone replacement therapy on cognitive brain aging. Ann N Y Acad Sci. 2002;949:203–214
  9. Faulkner DL, Young C, Hutchins D, McCollam JS. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause. 1998;5:226–229
  10. Regan MM, Emond SK, Attardo MJ, Parker RA, Greenspan SL. Why do older women discontinue hormone replacement therapy?. J Womens Health Gend Based Med. 2001;10:343–350
  11. Vihtamäki T, Savilahti R, Tuimala R. Why do postmenopausal women discontinue hormone replacement therapy?. Maturitas. 1999;33:99–105
  12. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy, II: neoplasia. Am J Obstet Gynecol. 1979;133:537–547
  13. Hill DA, Weiss NS, LaCroix AZ. Adherence to postmenopausal hormone therapy during the year after the initial prescription: a population-based study. Am J Obstet Gynecol. 2000;182:270–276
  14. Dören M, Reuther G, Minne HW, Schneider HPG. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol. 1995;173:1446–1451
  15. Archer DF, Pickar JH, Bottiglioni F, for the Menopause Study Group . Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol. 1994;83:686–692
  16. Luciano AA, De Souza MJ, Roy MP, Schoenfeld MJ, Nulsen JC, Halvorson CV. Evaluation of low-dose estrogen and progestin therapy in postmenopausal women: a double-blind, prospective study of sequential versus continuous therapy. J Reprod Med. 1993;38:207–214
  17. Symons J, Kempfert N, Speroff L, for the Femhrt Study Investigators . Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. Obstet Gynecol. 2000;96:366–372
  18. Archer DF, Furst K, Tipping D, Dain M, Vendepol L. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. Obstet Gynecol. 1999;84:498–503
  19. Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. Am J Obstet Gynecol. 1990;162:1534–1542
  20. Simon JA, Symons JP. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. Menopause. 2001;8:321–327
  21. Wyeth . Prempro prescribing information. http://www.wyeth.com/products/all.asp
  22. Speroff L, Rowan J, Symons J, Genant H, Wilborn W, for the CHART Study Group . The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). JAMA. 1996;276:1397–1402
  23. Lebovic DI, Shifren JL, Ryan IP, Mueller MD, Korn AP, Darney PD, et al.  Ovarian steroid and cytokine modulation of human endometrial angiogenesis. Hum Reprod. 2000;15(suppl):67–77
  24. Van de Weijer PHM, Bartensen R, de Vries M, Kenemans P. Relationship of estradiol levels to breakthrough bleeding during continuous combined hormone replacement therapy. Obstet Gynecol. 1999;93:551–557
  25. Kuhnz W, Heuner A, Hümpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl estradiol in postmenopausal women. Contraception. 1997;56:379–385

☆ Supported by Pfizer Global Research & Development.

☆☆ Reprint requests: James A. Simon, MD, Women's Health Research Center, Laurel, MD 20707. E-mail: jasimon@whrc.net

PII: S0002-9378(02)71434-8

doi: 10.1067/mob.2003.104

American Journal of Obstetrics & Gynecology
Volume 188, Issue 1 , Pages 92-99 , January 2003

Article Tools

* Image Usage & Resolution